Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 21:12:1631-1648.
doi: 10.2147/JPR.S203553. eCollection 2019.

Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study

Affiliations

Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study

Manabu Akazawa et al. J Pain Res. .

Abstract

Purpose: Musculoskeletal diseases, including osteoarthritis (OA) and low back pain (LBP), are the leading causes of years lived with disability, and are associated with lowered quality-of-life, lost productivity, and increased healthcare costs. However, information publicly available regarding the Japanese real-world usage of prescription medications is limited. This study aimed to describe the clinical characteristics of patients with OA and chronic LBP (CLBP), and to investigate the patterns of medications and opioid use in Japanese real-world settings. Materials and methods: A retrospective study was conducted using a Japanese administrative claims database between 2013 and 2017. The outcomes were patient characteristics and prescription medications, and they were evaluated separately for OA and CLBP. Results: The mean age of 118,996 patients with OA and 256,402 patients with CLBP was 68.8±13.1 years and 64.8±16.4 years, respectively. Approximately 90% of patients with OA and CLBP were prescribed non-steroidal anti-inflammatory drugs (NSAIDs). Other prescriptions included hyaluronate injection (35.6%), acetaminophen (21.4%), and steroid injection (20.0%) in patients with OA, and pregabalin (39.0%) and acetaminophen (22.4%) in patients with CLBP. Weak opioids were prescribed to 10.7% and 20.6% of patients with OA and CLBP, respectively. The prescription of COX-2 inhibitors (OA: +6.5%; CLBP: +6.7%) and acetaminophen (OA: +16.4%; CLBP: +14.4%) increased between 2013 and 2017. The first commonly prescribed medication among patients with OA and CLBP were NSAIDs; hyaluronate injection (patients with OA) and pregabalin (patients with CLBP) were also common first-line medications. Acetaminophen, steroid injection (patients with OA), and weak opioids were prescribed more in the later phases of treatment. Conclusion: Most patients were prescribed limited classes of pain drugs, with NSAIDs being the most common pain medication in Japan for patients with OA and CLBP. Opioid prescription was uncommon, and were weak opioids when prescribed.

Keywords: chronic low back pain; non-steroidal anti-inflammatory drugs; opioid; osteoarthritis; pain.

PubMed Disclaimer

Conflict of interest statement

Kanae Togo, Nozomi Ebata, and Koichi Fujii are employees of Pfizer Japan Inc. Noriko Harada is an employee of Pfizer R&D Japan G.K. Lucy Abraham is an employee and shareholder of Pfizer Ltd. Haruka Murano is an employee of Clinical Study Support Inc. Manabu Akazawa and Wataru Mimura were not financially compensated for their collaboration in this project or for the development of this manuscript. Manabu Akazawa reports personal fees from Pfizer, and Takeda, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study timeline with hypothetical patient journeys. Index date represents the date of the first pain drug prescription; Follow-up period represents from index date to the date of OA surgery or the end date of prescriptions, whichever occurred later. Abbreviation: OA, osteoarthritis.
Figure 2
Figure 2
Flow of patient extraction. Abbreviations: CLBP, chronic low back pain; MDV, Medical Data Vision Co., Ltd.; OA, osteoarthritis.

Similar articles

Cited by

References

    1. World Health Organization (WHO). World Health Statistics 2018: Monitoring Health for the SDGs, Sustainable Development Goals. Geneva: WHO; 2018.
    1. World Health Organization (WHO). Healthy life expectancy (HALE) data by country. Available from: http://apps.who.int/gho/data/view.main.HALEXv?lang=en. Accessed October9, 2018.
    1. Global Burden of Disease (GBD) Compare | Viz Hub. Seattle: the Institute for Health Metrics and Evaluation (IHME) from the University of Washington; 2017. Available from: https://vizhub.healthdata.org/gbd-compare/. Accessed October9, 2018.
    1. Sadosky AB, DiBonaventura M, Cappelleri JC, Ebata N, Fujii K. The association between lower back pain and health status, work productivity, and health care resource use in Japan. J Pain Res. 2015;8:119–130. - PMC - PubMed
    1. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence-based approach to the management of knee osteoarthritis: report of a task force of the standing committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–1155. doi:10.1136/ard.2003.011742 - DOI - PMC - PubMed